Super proud of our trials team today! We have randomised the first patient in the UK to a major phase 3 trial in pancreatic cancer that has the potential to change first line treatment for patients.

Delighted to have the opportunity to present to the NIHR strategy board on Birmingham’s leading pancreatic cancer trial portfolio with infant in tow (inset day equals daddy day care).

I would love to see a real world evidence study of giving mounjaro or ozempic to newly diagnosed type 2 diabetes patients in the nhs. It would be a gamechanger for patients and the nhs.

Ecstatic to see this out! Important implications for immune targeting in pancreatic cancer. Has been a labour of love! Lots of fantastic collaborators and important new early phase trials being set up!

www.nature.com/articles/s41...

Important study, this suggests that if give patients 8 cycles of neoadjuvant chemotherapy, no benefit of adjuvant. I’m sure most patients would prefer upfront chemotherapy.

jamanetwork.com/journals/jam...

Pan-RAS inhibitor RMC-6236 aka Daraxonrasib in patients with RAS-mutant pancreatic adenocarcinoma 🤯🤯🤯 #GI25
dailynews.ascopubs.org/do/pan-ras-i...

Looks like we are on the verge of something quite exciting in pancreatic cancer…

dailynews.ascopubs.org/do/pan-ras-i...

Preprint alert! Delighted to be part of this collaboration where we used a new fragmentomic method in a multi-analyte setting to understand which high risk pancreas lesions could become cancer. Potential large benefits for patients.

www.medrxiv.org/content/10.1...

This has been much delayed coming in. Still no coherent obesity plan for the UK. Biggest reason for the decline of healthcare of people and nhs. @rthonwesstreeting.bsky.social need to be more ambitious with obesity including earlier implementation of GLP-1 agonists and food reform.

I am genuinely perplexed on why the world seems to be deafeningly silent on women’s rights in Afganhistan. Where are the protests and the outrage?

www.bbc.com/news/article...

In the University of Birmingham alumni magazine, it was announced that a former patient of mine and their family had kindly philanthropically raised funds for me and colleagues to have a student to study an understudied part of the immune system in pancreatic cancer.
www.oldjoe.co.uk/article/reas...

🤓 Our team enjoyed fantastic presentations by Adam Cunningham, Arzoo Patel with Palak Trivedi and Shivan Sivakumar on immunity to Salmonella, the gut microbiome in autoimmune liver diseases and pancreatic cancer therapies.

As we come to the end of pancreatic cancer awareness month, as an oncologist I have never seen so much excitement in drug development in this setting. From personalised vaccines to off the shelf and kras inhibitors, PRMT5 inhibitors, CD40 agonists and CD73 inhibitors to name a few.